Search

This article discusses three cases of patients who developed cytokine release syndrome (CRS) during treatment for various conditions. The first case involves a 59-year-old man with diffuse large B-cell lymphoma who experienced CRS after receiving tisagenlecleucel. Despite treatment with various medications, his condition did not improve until he was given anakinra. The second case involves a 71-year-old woman with follicular lymphoma who developed CRS after receiving axicabtagene ciloleucel. She was treated with dexamethasone and tocilizumab. The third case involves a 15-year-old boy with relapsed B-cell acute lymphoblastic leukemia who experienced CRS after receiving tisagenlecleucel. Despite initial treatment with paracetamol and hydrocortisone, his condition worsened and he was eventually treated with tocilizumab. [Extracted from the article]

A 74-year-old man with diffuse large B-cell lymphoma developed cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) during treatment with axicabtagene ciloleucel. Despite receiving tocilizumab, dexamethasone, anakinra, and methylprednisolone for ICANS, the patient did not show any improvement (lack of efficacy). His condition worsened, and he eventually died after three months of symptom onset. Autopsy was not performed. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 34-year-old woman developed Cytokine release syndrome (CRS) and immune-effector-cell-associated neurotoxicity syndrome (ICANS) during treatment with CAR-T cell therapy with axicabtagene ciloleuce and lymphodepleting with fludarabine and cyclophosphamide for diffuse large B-cell lymphoma stage IV. Hence, plasma exchange therapy was commenced on day 22 and repeat CSF on day 22 after 7 days of treatment with foscarnet for HHV 6 showed persistent HHV 6 infections. [Extracted from the article]